A Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
This is a two-part Phase 1 placebo-controlled, double-blind, randomized single and multiple
ascending dose study. In Part A, CAT-2003 is administered as a single dose; at two doses
(1000 and 2000 mg), subjects will return for a second dose of CAT-2003 or placebo after a
high fat meal. In Part B, CAT-2003 is administered for 14 consecutive days.